Becton, Dickinson and Company (NYSE:BDX) Receives Consensus Rating of “Hold” from Analysts

Posted by George Bondi on Aug 31st, 2026

Shares of Becton, Dickinson and Company (NYSE:BDX – Get Free Report) have received a consensus recommendation of “Hold” from the seventeen analysts that are presently covering the firm, Marketbeat.com reports. One equities research analyst has rated the stock with a sell recommendation, eight have given a hold recommendation and eight have issued a buy recommendation on the company. The average 12-month price objective among analysts that have issued a report on the stock in the last year is $185.6667.

Several research firms have weighed in on BDX. Royal Bank Of Canada lifted their target price on Becton, Dickinson and Company from $180.00 to $190.00 and gave the stock a “sector perform” rating in a report on Thursday, August 13th. TD Cowen increased their price target on Becton, Dickinson and Company from $163.00 to $182.00 and gave the stock a “hold” rating in a report on Wednesday, August 5th. Piper Sandler raised their price target on Becton, Dickinson and Company from $161.00 to $175.00 and gave the stock a “neutral” rating in a research report on Friday, August 7th. Citigroup reiterated a “buy” rating on shares of Becton, Dickinson and Company in a report on Thursday, August 13th. Finally, The Goldman Sachs Group decreased their price objective on Becton, Dickinson and Company from $156.00 to $150.00 and set a “neutral” rating for the company in a research report on Wednesday, May 27th.

Read Our Latest Stock Analysis on Becton, Dickinson and Company

Becton, Dickinson and Company Stock Up 0.1%

Shares of NYSE:BDX opened at $189.71 on Monday. The company has a 50 day moving average price of $166.14 and a two-hundred day moving average price of $160.20. The company has a debt-to-equity ratio of 0.55, a quick ratio of 0.51 and a current ratio of 0.87. The company has a market capitalization of $52.27 billion, a PE ratio of 57.14, a PEG ratio of 13.36 and a beta of 0.19. Becton, Dickinson and Company has a 52 week low of $127.59 and a 52 week high of $193.07.

Becton, Dickinson and Company (NYSE:BDX – Get Free Report) last announced its quarterly earnings results on Thursday, August 6th. The medical instruments supplier reported $3.23 earnings per share for the quarter, topping analysts’ consensus estimates of $3.14 by $0.09. Becton, Dickinson and Company had a net margin of 4.52% and a return on equity of 14.79%. The company had revenue of $4.98 billion for the quarter, compared to analysts’ expectations of $4.89 billion. During the same period last year, the firm posted $3.68 earnings per share. The business’s quarterly revenue was up 5.4% compared to the same quarter last year. Becton, Dickinson and Company has set its FY 2026 guidance at 12.620-12.720 EPS. Analysts forecast that Becton, Dickinson and Company will post 12.67 earnings per share for the current year.

Becton, Dickinson and Company Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Wednesday, September 30th. Stockholders of record on Wednesday, September 9th will be issued a $1.05 dividend. This represents a $4.20 annualized dividend and a dividend yield of 2.2%. The ex-dividend date is Wednesday, September 9th. Becton, Dickinson and Company’s dividend payout ratio is 126.51%.

Insider Activity at Becton, Dickinson and Company

In related news, CEO Thomas E. Polen, Jr. sold 4,152 shares of the business’s stock in a transaction on Thursday, August 13th. The shares were sold at an average price of $185.00, for a total value of $768,120.00. Following the sale, the chief executive officer directly owned 110,163 shares of the company’s stock, valued at approximately $20,380,155. The trade was a 3.63% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Roland Goette sold 2,438 shares of the stock in a transaction dated Tuesday, August 11th. The stock was sold at an average price of $180.84, for a total value of $440,887.92. Following the transaction, the executive vice president owned 14,856 shares of the company’s stock, valued at approximately $2,686,559.04. This trade represents a 14.10% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 9,105 shares of company stock worth $1,590,208 over the last three months. 0.40% of the stock is currently owned by insiders.

Institutional Trading of Becton, Dickinson and Company

A number of institutional investors have recently modified their holdings of the company. Imprint Wealth LLC acquired a new stake in Becton, Dickinson and Company in the 3rd quarter valued at approximately $25,000. SHP Wealth Management acquired a new position in Becton, Dickinson and Company during the 4th quarter worth approximately $26,000. Meeder Asset Management Inc. boosted its position in Becton, Dickinson and Company by 152.2% during the 1st quarter. Meeder Asset Management Inc. now owns 169 shares of the medical instruments supplier’s stock worth $27,000 after acquiring an additional 102 shares during the last quarter. Main Street Group LTD bought a new position in shares of Becton, Dickinson and Company during the 1st quarter worth approximately $29,000. Finally, Bell Investment Advisors Inc bought a new position in shares of Becton, Dickinson and Company during the 2nd quarter worth approximately $29,000. 86.97% of the stock is currently owned by institutional investors.

About Becton, Dickinson and Company

(Get Free Report)

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.